InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $16.500 -3.73 (-18.44%)+
Announcement
Release
6 Nov 2025 9:59AM
Price at Release
$20.230
Full Release
download
Summary
Neuren Pharmaceuticals Limited announced record net sales of its drug DAYBUE™ (trofinetide) amounting to US$101.1 million in Q3 2025, reflecting an 11% increase from Q3 2024 and a 5% increase from Q2 2025. This milestone was achieved with over 1,000 patients receiving shipments for the first time and a significant increase in new patient prescriptions from community-based physicians. Neuren also reported an increase in royalty income, amounting to A$16.4 million for Q3 2025. The company anticipates a full year royalty income of between A$63 million and A$66 million, assuming Acadia's guidance is met. Neuren is further expanding its market presence with ongoing programs and trials in multiple regions outside North America.
Key Points
  • Record DAYBUE™ net sales of US$101.1 million in Q3 2025.
  • 11% sales increase from Q3 2024 and 5% from Q2 2025.
  • Over 1,000 patients received shipments for the first time.
  • 74% of new patient prescriptions from community physicians.
  • Neuren earned A$16.4 million in Q3 2025 royalty income.
  • Anticipated full year royalty income of A$63 – 66 million in 2025.
  • Expanded market presence includes named patient programs and trials in Europe, Israel, Middle East, and Latin America.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.